Immunological and molecular studies in tumors of the urinary bladder

Darrell Davidson, Antonio Lopez-Beltran, Sean R. Williamson, Shaobo Zhang, Rodolfo Montironi, Liang Cheng

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

With accumulating molecular knowledge of bladder cancer, we are about to bridge the gap between genetic findings and clinical outcomes. Assessment of key genetic pathways and expression profiles should establish a set of molecular markers to predict the likelihood of tumor recurrence and progressive transformation. FGFR3 and TP53 mutation pathway identification, correlating with low grade and high grade bladder cancer respectively, provides not only tools for bladder cancer diagnosis and prognosis, but also a potential therapeutic target for each category of bladder cancer. Therapies targeting FGFR3, TP53 or their key downstream pathways could become new options for bladder cancer management. Urinary bladder cancer is a heterogeneous disease with diverse morphologic and clinical manifestations [1, 2].Three major risks for patients after initial management are recurrence, progression and metastasis. These risks are well known for each stage of the disease, but are not sufficiently quantifiable for individual prospective risk assessment. Clinical and pathological parameters are widely used for prediction of clinical outcomes, but these parameters show limited utility in prediction of tumor recurrence. Identification of reliable parameters of high risk for tumor recurrence nd progression would be valuable when advising patients regarding surveillance measures and aggressiveness of therapy.

Original languageEnglish
Title of host publicationImmunological and Molecular Diagnosis of Cancer
PublisherNova Science Publishers, Inc.
Pages193-207
Number of pages15
ISBN (Print)9781617289491
StatePublished - 2012

Fingerprint

Urinary Bladder Neoplasms
Tumors
Urinary Bladder
Recurrence
Neoplasms
Risk assessment
Therapeutics
Neoplasm Metastasis
Mutation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Davidson, D., Lopez-Beltran, A., Williamson, S. R., Zhang, S., Montironi, R., & Cheng, L. (2012). Immunological and molecular studies in tumors of the urinary bladder. In Immunological and Molecular Diagnosis of Cancer (pp. 193-207). Nova Science Publishers, Inc..

Immunological and molecular studies in tumors of the urinary bladder. / Davidson, Darrell; Lopez-Beltran, Antonio; Williamson, Sean R.; Zhang, Shaobo; Montironi, Rodolfo; Cheng, Liang.

Immunological and Molecular Diagnosis of Cancer. Nova Science Publishers, Inc., 2012. p. 193-207.

Research output: Chapter in Book/Report/Conference proceedingChapter

Davidson, D, Lopez-Beltran, A, Williamson, SR, Zhang, S, Montironi, R & Cheng, L 2012, Immunological and molecular studies in tumors of the urinary bladder. in Immunological and Molecular Diagnosis of Cancer. Nova Science Publishers, Inc., pp. 193-207.
Davidson D, Lopez-Beltran A, Williamson SR, Zhang S, Montironi R, Cheng L. Immunological and molecular studies in tumors of the urinary bladder. In Immunological and Molecular Diagnosis of Cancer. Nova Science Publishers, Inc. 2012. p. 193-207
Davidson, Darrell ; Lopez-Beltran, Antonio ; Williamson, Sean R. ; Zhang, Shaobo ; Montironi, Rodolfo ; Cheng, Liang. / Immunological and molecular studies in tumors of the urinary bladder. Immunological and Molecular Diagnosis of Cancer. Nova Science Publishers, Inc., 2012. pp. 193-207
@inbook{0b3bfe0750664034861027909e64b908,
title = "Immunological and molecular studies in tumors of the urinary bladder",
abstract = "With accumulating molecular knowledge of bladder cancer, we are about to bridge the gap between genetic findings and clinical outcomes. Assessment of key genetic pathways and expression profiles should establish a set of molecular markers to predict the likelihood of tumor recurrence and progressive transformation. FGFR3 and TP53 mutation pathway identification, correlating with low grade and high grade bladder cancer respectively, provides not only tools for bladder cancer diagnosis and prognosis, but also a potential therapeutic target for each category of bladder cancer. Therapies targeting FGFR3, TP53 or their key downstream pathways could become new options for bladder cancer management. Urinary bladder cancer is a heterogeneous disease with diverse morphologic and clinical manifestations [1, 2].Three major risks for patients after initial management are recurrence, progression and metastasis. These risks are well known for each stage of the disease, but are not sufficiently quantifiable for individual prospective risk assessment. Clinical and pathological parameters are widely used for prediction of clinical outcomes, but these parameters show limited utility in prediction of tumor recurrence. Identification of reliable parameters of high risk for tumor recurrence nd progression would be valuable when advising patients regarding surveillance measures and aggressiveness of therapy.",
author = "Darrell Davidson and Antonio Lopez-Beltran and Williamson, {Sean R.} and Shaobo Zhang and Rodolfo Montironi and Liang Cheng",
year = "2012",
language = "English",
isbn = "9781617289491",
pages = "193--207",
booktitle = "Immunological and Molecular Diagnosis of Cancer",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Immunological and molecular studies in tumors of the urinary bladder

AU - Davidson, Darrell

AU - Lopez-Beltran, Antonio

AU - Williamson, Sean R.

AU - Zhang, Shaobo

AU - Montironi, Rodolfo

AU - Cheng, Liang

PY - 2012

Y1 - 2012

N2 - With accumulating molecular knowledge of bladder cancer, we are about to bridge the gap between genetic findings and clinical outcomes. Assessment of key genetic pathways and expression profiles should establish a set of molecular markers to predict the likelihood of tumor recurrence and progressive transformation. FGFR3 and TP53 mutation pathway identification, correlating with low grade and high grade bladder cancer respectively, provides not only tools for bladder cancer diagnosis and prognosis, but also a potential therapeutic target for each category of bladder cancer. Therapies targeting FGFR3, TP53 or their key downstream pathways could become new options for bladder cancer management. Urinary bladder cancer is a heterogeneous disease with diverse morphologic and clinical manifestations [1, 2].Three major risks for patients after initial management are recurrence, progression and metastasis. These risks are well known for each stage of the disease, but are not sufficiently quantifiable for individual prospective risk assessment. Clinical and pathological parameters are widely used for prediction of clinical outcomes, but these parameters show limited utility in prediction of tumor recurrence. Identification of reliable parameters of high risk for tumor recurrence nd progression would be valuable when advising patients regarding surveillance measures and aggressiveness of therapy.

AB - With accumulating molecular knowledge of bladder cancer, we are about to bridge the gap between genetic findings and clinical outcomes. Assessment of key genetic pathways and expression profiles should establish a set of molecular markers to predict the likelihood of tumor recurrence and progressive transformation. FGFR3 and TP53 mutation pathway identification, correlating with low grade and high grade bladder cancer respectively, provides not only tools for bladder cancer diagnosis and prognosis, but also a potential therapeutic target for each category of bladder cancer. Therapies targeting FGFR3, TP53 or their key downstream pathways could become new options for bladder cancer management. Urinary bladder cancer is a heterogeneous disease with diverse morphologic and clinical manifestations [1, 2].Three major risks for patients after initial management are recurrence, progression and metastasis. These risks are well known for each stage of the disease, but are not sufficiently quantifiable for individual prospective risk assessment. Clinical and pathological parameters are widely used for prediction of clinical outcomes, but these parameters show limited utility in prediction of tumor recurrence. Identification of reliable parameters of high risk for tumor recurrence nd progression would be valuable when advising patients regarding surveillance measures and aggressiveness of therapy.

UR - http://www.scopus.com/inward/record.url?scp=84895367417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895367417&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84895367417

SN - 9781617289491

SP - 193

EP - 207

BT - Immunological and Molecular Diagnosis of Cancer

PB - Nova Science Publishers, Inc.

ER -